FDA approves Dermira's Qbrexza for treatment of primary armpit hyperhidm
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
primary armpit hyperhidm, often referred to as excessive underarm sweating, is a chronic skin disease that causes sweating to exceed the amount required for normal body temperature regulationThe exact cause of the disease is unclear, but it affects nearly 10 million people in the United States, with similar prevalence rates in men and womenrecently, the Bio
Medicines(The Company(announced that the FDAof theFDA (glycopyrronium) is available for local treatment in children and adults 9 years and older with primary armpit hyperhidrosisQbrexza, an anticholinergic drug, promises to offer treatment to these patientsIt can be applied directly to the skin and prevents the production of sweat by inhibiting the activation of the sweat glandsThis Approval of Qbrexza is based on the results of two Phase 3 clinicaltrial
s (and ATMOS-2) that assessed the efficacy and safety of Qbrexza in patients with primary armpit hyperhidoryboth trials wereassessed an absolute change in sweat ingresss (the amount of sweat produced by patients) compared to the baseline after treatment with Qbrexza, and a ratio of at least 4 points to the baseline of the patient's severance of sweating (the patient report results of dermira proprietary patients (PRO)instrument
s/oassessment (the daily record of measured underarm sweats (ASDD) was assessed
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
